RxDoctor Payments Data

Laura McPheeters

Nurse Practitioner · Tucson, AZNPI 1033669387

Payments from drug & device makers

$1,571in general payments, 2019–2025

Across 19 payments — averaging $82.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$442
  • Johnson & Johnson$225
  • Bristol Myers Squibb$125
  • Sobi, Inc$125
  • AstraZeneca$122
  • Astellas Pharma US Inc$116
  • plus $416 from 6 others

What the payments were for

  • Food & beverage$1,19476%
  • Education$37724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,571 in reported general payments places this provider in the 85th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$42,336
Medicare patients
192
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide34$605,841
VenclextaVenetoclax22$81,440
ValacyclovirValacyclovir Hcl35$2,020
Levofloxacin42$1,886
Acyclovir84$1,448
Fluconazole37$1,396
Dexamethasone40$575
Naloxone Hcl11$571
Hydroxyurea13$484
Oxycodone Hcl25$415
Prochlorperazine Maleate11$186
Potassium Chloride22$180
Gabapentin18$173
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$74
Prednisone19$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$125$605,84134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →